Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Saturday, 17. July 2021 SSC Session 08:00 - 10:00 R1 Factor VIII, Factor IX and Rare Coagulation Disorders Introduction 08:00 - 08:02 Speaker: Johnny Mahlangu, ZA Non-Factor Replacement Therapies 08:02 - 08:02 Moderators: Johnny Mahlangu, South Africa, Tarek Owaidah, Saudi Arabia In Patients on Non-Factor Therapies, Exposure to Clotting 08:02 - 08:14 Factor Replacement Should Be Early (Debate) Speaker: Manuel Carcao, CA In Patients on Non-Factor Therapies, Exposure to Clotting 08:14 - 08:26 Factor Replacement Should Be Early (Debate) Speaker: Jayanthi Alamelu, GB Non-Factor Replacement Therapy Versus Factor Replacement 08:26 - 08:38 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Bhavya Doshi, US Non-Factor Replacement Therapy Versus Factor Replacement 08:38 - 08:50 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Gili Kenet, IL Beyond Annualized Bleed Rates What Should Be the Alternative 08:50 - 09:02 Endpoints for Non-Replacement Therapies Speaker: Alok Srivastava, IN Q&A Session 09:02 - 09:06 Gene Therapy 09:06 - 09:06 Moderators: Valder Arruda, United States, Savita Rangarajan, United Kingdom Anti Adeno-Associated Virus Antibodies Antibodies: What Are 09:06 - 09:18 the Standardization Issues? Speaker: David Lillicrap, CA Rationale for Adeno-associated Virus (AAV) Mediated Gene 09:24 - 09:30 Therapy in Patients With Anti Adeno-associated Virus Antibodies Speaker: David Cooper, NL What Should We Be Following-up Post Gene Therapy? 09:30 - 09:42 Speaker: Barbara A. Konkle, US Q&A Session 09:42 - 09:46 New SSC Projects 1 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. 09:46 - 09:46 Moderators: Sabine Heine, Germany, John Pasi, United Kingdom Proposal for New Nomenclature for Previously Untreated 09:46 - 09:50 Patients Speaker: Guy Young, US Proposal for Value Assignment to the WHO 9th International 09:50 - 09:54 Standard for Factor VIII Concentrate Speaker: Sanj Raut, GB Q&A Session / Conclusion 09:54 - 10:00 SSC Session 08:00 - 10:00 R2 Platelet Immunology Moderator: Tamam Bakchoul, Germany 08:00 - 08:00 Introduction 08:00 - 08:01 Speaker: Tamam Bakchoul, DE Platelet Immunology and COVID-19 08:01 - 08:01 Antibody-Mediated Procoagulant Platelets in COVID-19 08:01 - 08:11 Speaker: Karina Althaus, DE Platelet Activating Immune Complexes in COVID-19 08:11 - 08:21 Speaker: Stefan Jevtic, CA Discussion I / Q&A Session I 08:21 - 08:31 Speaker: Steve McKenzie, US Heparin Induced Thrombocytopenia 08:31 - 08:31 Standardization of Functional Heparin Induced 08:31 - 08:41 Thrombocytopenia Assays Speaker: Ishac Nazy, CA 5B9 mAB as Internal Control for Heparin Induced 08:41 - 08:51 Thrombocytopenia Testing Speaker: Claire Pouplard, FR Discussion II / Q&A Session II 08:51 - 08:56 Speaker: Ruchika Sharma, US Immune Thrombocytopenia 08:56 - 08:56 Standardization of Clinical Outcomes in Immune 08:56 - 09:06 Thrombocytopenia Speaker: Rachael Grace, US Guideline for the Management of Critical ITP Bleeding 09:06 - 09:16 Speaker: Donald M. Arnold, CA 2 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Discussion III / Q&A Session III 09:16 - 09:21 Speaker: Philip Choi, AU Fetal and Neonatal Alloimmune Thrombocytopenia 09:21 - 09:21 Recent Advances in the Antenatal Diagnosis of Fetal and 09:21 - 09:31 Neonatal Alloimmune Thrombocytopenia Speaker: Ruchika Sharma, US Update on the SSC Survey On the Postnatal Fetal and Neonatal 09:31 - 09:36 Alloimmune Thrombocytopenia Speaker: Maria Therese Ahlen, NO Discussion IV / Q&A Session IV 09:36 - 09:41 Speaker: Rachael Grace, US Update On On-going and Proposed Projects 09:41 - 09:41 Platelet Autoantibody Detection in Immune Thrombocytopenia 09:41 - 09:46 Speaker: Maria Therese Ahlen, NO Identification of Good Platelet Responders For Functional 09:46 - 09:51 Heparin Induced Thrombocytopenia Assays Speaker: Steve McKenzie, US Summary and Roadmap 09:51 - 09:56 Speaker: Tamam Bakchoul, DE Discussion V / Q&A Session V 09:56 - 10:00 Speaker: Tamam Bakchoul, DE SSC Session 08:00 - 10:00 R3 Vascular Biology Introduction 08:00 - 08:01 Speaker: Johannes Thaler, AT Moderators: Claudine Graf, Germany, Kimberly Martinod, 08:01 - 08:01 Belgium An Update on the SSC Neutrophil Extracellular Trap (NETs) 08:01 - 08:13 Standardization Project Speaker: Kimberly Martinod, BE Enzyme-Linked Immunoassay (ELISA) Detection of MPO-DNA 08:13 - 08:25 Complexes in Human Plasma Speaker: Christine Brostjan, AT Establishment of a Flow Cytometric Panel for the 08:25 - 08:37 Characterization of Factor X Expressing Tumor Macrophages in Mice Speaker: Claudine Graf, DE Q&A Session 08:37 - 08:42 3 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Moderators: Johannes Thaler, Austria, David Smadja, France, 08:42 - 08:42 Juan Melero-Martin, United States Identification of Markers That Can Separate Procoagulant 08:42 - 08:54 Platelets From Apoptotic Platelets Speaker: Emma Josefsson, AU Endothelial Cells and COVID-19: Marker or Active Partner 08:54 - 09:06 Speaker: David Smadja, FR Endothelial Senescence in Chronic Lung Disease and Possible 09:06 - 09:18 Implications in Severe COVID-19: Studies on ECFC Speaker: Koralia Paschalaki, GB Q&A Session 09:18 - 09:23 Moderator: Romaric Lacroix, France 09:23 - 09:23 ISEV-ISAC-ISTH EV Flow Cytometry Working Group Updates 09:23 - 09:33 Speaker: Joshua A. Welsh, US Standardization of Extracellular Vesicle Concentration 09:33 - 09:43 Measurements - An Update on the METVES II Project Speaker: Britta A. Bettin, NL Extracellular Vesicle-Tissue Factor Assays in COVID-19 Time 09:43 - 09:53 Speaker: Amandine Bonifay, FR Q&A Session 09:53 - 10:00 SSC Session 08:00 - 10:00 R4 Lupus Anticoagulant/Antiphospholipid Antibodies Moderator: Katrien Devreese, Belgium, Hannah Cohen, United 08:00 - 08:00 Kingdom Introduction 08:00 - 08:03 Speaker: Katrien Devreese, BE Treatment of Antiphospholipid Antibody Syndrome 08:03 - 08:03 Registry on Augmented Antithrombotic Treatment Regimens for 08:03 - 08:13 Patients With Arterial Thrombotic Antiphospholipid Antibody Syndrome Speaker: Sam Schulman, CA Current Treatments Practice in Women With Obstetric 08:13 - 08:18 Antiphospholipid Antibody Syndrome and Women With Obstetrical Morbidity and “Non-Criteria” Antiphospholipid Antibody Syndrome and Adverse Obstetrical Outcomes: Cora International Registry Speaker: Patricia Casais, AR Current Treatments Practice in Women With Obstetric 08:18 - 08:23 4 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Antiphospholipid Antibody Syndrome and Women With Obstetrical Morbidity and “Non-Criteria” Antiphospholipid Antibody Syndrome and Adverse Obstetrical Outcomes: Cora International Registry Speaker: Cristina Belizna, FR Survey on Diagnosis and Antithrombotic Treatment in 08:23 - 08:33 Antiphospholipid Antibody Syndrome Patients With Ischemic Stroke, Other Brain Ischemic Injury or Arterial Thromboembolism in Other Sites Speaker: Hannah Cohen, GB Update on International Registry of Thrombotic 08:33 - 08:43 Antiphospholipid Antibody Syndrome Patients Treated With Direct Oral Anticoagulants Speaker: Stéphane Zuily, FR Q&A Session on Registries On Treatment of Antiphospholipid 08:43 - 08:53 Antibody Syndrome Laboratory Diagnosis of Antiphospholipid Antibody Syndrome 08:53 - 08:53 Why Antiphosphatidylserine/Prothrombin Antibodies and Other 08:53 - 09:05 Second Level Antiphospholipid Antibody Tests Should Be Added to Improve on the Definition of Antiphospholipid Antibody Syndrome Speaker: Vittorio Pengo, IT An International, Multi-Centre Study to Validate the Taipan 09:05 - 09:17 Snake Venom Time as a Lupus Anticoagulant Screening Test With Ecarin Time as Confirmatory Test Speaker: Gary Moore, GB Qualitative Classification of Anticardiolipin and Anti- 09:17 - 09:29 beta2glycoprotein I Antibodies Speaker: Katrien Devreese, BE Q&A Session on Laboratory Diagnosis 09:29 - 09:37 Standardization of Thrombin Generation Assays 09:37 - 09:49 Speaker: Marisa Ninivaggi, NL Update on the SKYLARK Project (Successive Follow up of 09:49 - 09:54 Antiphospholipid Antibodies Fluctuations in Patients With Clinical Sydney Criteria for Antiphospholipid Antibody Syndrome) and the Nymphea Project (Antiphospholipid Antibodies and Lymphoma) Speaker: Cristina Belizna, FR Q&A Session and Closing Remarks 09:54 - 10:00 SSC Session 08:00 - 10:00 R5 Women’s Health in Thrombosis and Hemostasis 5 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Introduction/Outline of the Women’s SSC and Overview of 08:00 - 08:10 Activities Speaker: Maha Othman, CA Update On On-going SSC Projects - Moderators: Ann Kinga Malinowski, Canada, Patricia Casais, Argentina Physicians’ Knowledge and Practices of Management of 08:10 - 08:20 COVID-19 Coagulopathies in Pregnancy Speaker: Stefan D. Jevti, CA Obstetrics and Gynecological Outcomes of Women with Platelet 08:20 - 08:30 Function Disorders Speaker: Deborah Obeng-Tuudah, GB Women International TEAM (WiTEAM) Study on Placenta- 08:30 - 08:40 Mediated Pregnancy Complications and Thrombophilia Speaker: Mariola Ortin Marci, ES COVID-19 and Pregnancy 08:40 - 08:50 Speaker: A. Kinga